Camp4 Therapeutics (CAMP) EBITDA Margin (2023 - 2026)
Camp4 Therapeutics recorded quarterly EBITDA Margin of 1416.62% in Q1 2026, up 87.76% quarter-over-quarter from 11575.86% in Q4 2025, and up 3245.0% year-over-year from 42.35% in Q1 2025.
Camp4 Therapeutics' EBITDA Margin history runs 4 years deep, the most recent figure standing at 1416.62% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 3245.0% year-over-year to 1416.62%; the TTM figure through Mar 2026 stood at 2193.72% (up 123489.0% YoY), while the FY2025 annual figure was 2298.54%, up 564486.0% from the prior year.
- EBITDA Margin came in at 1416.62% for Q1 2026 at Camp4 Therapeutics, up from 11575.86% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 840.81% in Q2 2025 to a low of 11575.86% in Q4 2025.
- A 4-year average of 3222.85% and a median of 1899.25% in 2025 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin slumped 953921 bps in 2025 and jumped 3245 bps in 2026, its largest moves.
- Camp4 Therapeutics' EBITDA Margin stood at 3341.71% in 2023, then jumped by 39 bps to 2036.66% in 2024, then plunged by 468 bps to 11575.86% in 2025, then soared by 88 bps to 1416.62% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1416.62%, 11575.86%, and 1899.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Camp4 Therapeutics | 245.89 Mn | 245.89 Mn | - | -1,416.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,416.62% |
| Dec 31, 2025 | -11,575.86% |
| Sep 30, 2025 | -1,899.25% |
| Jun 30, 2025 | -840.81% |
| Mar 31, 2025 | -1,449.07% |
| Dec 31, 2024 | -2,036.66% |
| Sep 30, 2023 | -3,341.71% |